Clinical trials: Coronary Artery Disease Progression
Coronary Arteriosclerosis
This Study Uses Ultrasound to Determine Whether Atorvastatin or Pravastatin Effects the Progression of Coronary Plaque.
This study was designed to assess the effects on coronary artery plaque using aggressive lipid-lowering therapy versus moderate lipid-lowering therapy.
- Trial name
- NCT00380939
- Testing
- Atorvastatin, Pravastatin
- Where
- 36 sites in United States
- Volunteers
- 600 people
- Sponsor
- Pfizer
Coronary Artery Disease (CAD), Coronary Atherosclerosis
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
The study will assess the change in coronary atherosclerotic disease as determined by intravascular ultrasound (IVUS) for aliskiren compared to placebo when given in addition to standard therapy in patients with coronary artery…
- Trial name
- AQUARIUS (NCT00853827)
- Testing
- Aliskiren
- Where
- 129 sites in United States, Argentina and 9 more
- Volunteers
- 613 people
- Sponsor
- Novartis Pharmaceuticals
Atherosclerosis, Coronary Artery Disease
MARS - Monitored Atherosclerosis Regression Study
The purpose of this study is to determine whether significant alterations in serum lipoproteins as provided by the drug lovastatin can substantially reduce atherosclerosis progression or even induce regression.
- Trial name
- NCT00116870
- Testing
- lovastatin
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- Merck Sharp & Dohme LLC
Cardiovascular Disease
A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease
This multicenter, double-blind, randomized, placebo-controlled study will evaluate the effect of dalcetrapib 600 mg on artherosclerotic disease progression, lipid profile and biomarker profile and long-term safety profile of…
- Trial name
- NCT01059682
- Testing
- Dalcetrapib
- Where
- 110 sites in United States, Canada and 3 more
- Volunteers
- 936 people
- Sponsor
- Hoffmann-La Roche
Coronary Heart Disease
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
This study will assess the effect of RO4607381, compared to placebo, on atherosclerotic plaque in patients with coronary heart disease (CHD) including patients with other CHD risk factors.
- Trial name
- NCT00655473
- Testing
- Dalcetrapib (RO4607381)
- Where
- 12 sites in United States, Canada
- Volunteers
- 130 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus
Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus
The purpose of this study was to determine the efficacy of pioglitazone, once daily (QD), compared to glimepiride on atherosclerotic disease measured by intravascular ultrasound.
- Trial name
- PERISCOPE (NCT00225277)
- Testing
- Pioglitazone, Glimepiride
- Where
- 79 sites in United States, Argentina and 2 more
- Volunteers
- 547 people
- Sponsor
- Takeda
PreDiabetes, Myocardial Infarction
Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction
It is hypothesize that, because dapagliflozin will reverse the metabolic defects responsible for the development of prediabetes (i.e.
- Conditions
- PreDiabetes, Myocardial Infarction, T2DM (Type 2 Diabetes Mellitus), CVD
- Trial name
- NCT03658031
- Testing
- Dapagliflozin 10mg
- Where
- Qatar
- Volunteers
- 576 people
- Sponsor
- Hamad Medical Corporation
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function.
- Trial name
- NCT06383390
- Testing
- Retatrutide
- Where
- 742 sites in United States, Argentina and 25 more
- Volunteers
- 10,000 people
- Sponsor
- Eli Lilly and Company
Coronary Artery Disease Progression
To Evaluate the Efficacy of Alirocumab for Neoatherosclerosis by Using OCT, in Comparison With Standard Statin Therapy
The aim of this study is to evaluate the efficacy of alirocumab for in-stent neoatherosclerosis by using optical coherence tomography, in comparison with standard statin therapy.
- Trial name
- POLARIS (NCT03533959)
- Testing
- Alirocumab
- Where
- Japan
- Volunteers
- 31 people
- Sponsor
- Kobe University
Coronary Artery Disease
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
CKJX839D12303 is a research study to determine if the study treatment, called inclisiran, in comparison to placebo taken in addition to statin medication can effectively reduce the total amount of plaque formed in the heart's…
- Trial name
- V-PLAQUE (NCT05360446)
- Testing
- Inclisiran sodium 300 mg
- Where
- 89 sites in United States, Argentina and 16 more
- Volunteers
- 610 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Artery Disease Progression
Relation Among HDL Functionality, Neoatherosclerosis and Target Lesion Revascularization
The aim of this study is to evaluate the relation among cholesterol uptake capacity which measure HDL functionality, neoathrosclerosis and target-lesion revascularization.
- Trial name
- NCT03540381
- Testing
- neoatherosclerosis
- Where
- Japan
- Volunteers
- 181 people
- Sponsor
- Kobe University
Coronary Artery Disease Progression
Effect of Rosuvastatin and Eicosapentaenoic Acid on Neoatherosclerosis: The LINK-IT Trial
This study aim to evaluate whether intensive lipid lowering therapy may improve the clinical outcomes in coronary artery disease patients with in-stent neoatherosclerosis, in comparison with standard therapy.
- Trial name
- NCT03192579
- Testing
- EPA and high dose rosuvastatin, Standard dose rosuvastatin
- Volunteers
- 50 people
- Sponsor
- Kobe University
CAD - Coronary Artery Disease
REWRITE-CAD Protocol: Risk Evaluation With AI-CPA to Reduce Progression and Improve Lifetime Care for Patients With Known Coronary Artery Disease
REWRITE-CAD is a prospective, randomized, multi-center trial assessing the management of asymptomatic participants with a history of PCI or MI who will undergo a blinded CCTA and be randomly assigned to either the test arm in…
- Trial name
- REWRITE-CAD (NCT07834372)
- Testing
- Heartflow Analysis
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- HeartFlow, Inc.
Coronary Atherosclerosis
STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)
The purpose of this study is to determine if rimonabant 20 mg once daily (od) administered during 18-20 months will reduce progression of coronary atherosclerosis as assessed by intravascular ultrasound (IVUS) when administered…
- Trial name
- NCT00124332
- Testing
- Rimonabant (SR141716)
- Where
- 9 sites in United States, Australia and 7 more
- Volunteers
- 839 people
- Sponsor
- Sanofi
Atherosclerosis
Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes
The purpose of this study is to test the safety and effectiveness of rosiglitazone against a sulfonylurea in reducing or slowing the development of atherosclerosis in the blood vessels of the heart.
- Trial name
- NCT00116831
- Testing
- Glipizide, rosiglitazone maleate
- Where
- 156 sites in United States, Argentina and 18 more
- Volunteers
- 672 people
- Sponsor
- GlaxoSmithKline
Coronary Stenosis, Periodontal Diseases
Periodontal Disease, Inflammation and Acute Coronary Syndromes
Recent studies have shown that the systemic inflammation caused by periodontal disease (PD) can determine important changes in the coronary arteries, favoring atherosclerosis progression and development of acute coronary…
- Conditions
- Coronary Stenosis, Periodontal Diseases, Acute Coronary Syndrome, Non-ST Elevation Myocardial Infarction
- Trial name
- ATHERODENT (NCT03395041)
- Testing
- cardiac imaging tests
- Where
- Romania
- Volunteers
- 149 people
- Sponsor
- Cardio Med Medical Center
Coronary Heart Disease
Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Coronary Artery Disease
The purpose of this study is to learn if CS-505 is safe and effective for slowing down or possibly reversing the buildup of tissue, cells and fatty deposits (plaque) in the blood vessels of the heart (coronary artery…
- Trial name
- NCT00185042
- Testing
- Pactimibe, CS-505
- Where
- 46 sites in United States
- Volunteers
- 534 people
- Sponsor
- Daiichi Sankyo
Heart Failure, Cardiomyopathies
Multimodal Physiologic State Intelligence Study
The OMNIPHYS study will investigate whether multimodal ultrasound and other routinely collected clinical and physiologic data can be combined with artificial intelligence to characterize changes in a person's physiologic state…
- Conditions
- Heart Failure, Cardiomyopathies, Pulmonary Hypertension, Myocarditis; Acute or Subacute
- Trial name
- OMNIPHYS (NCT07814118)
- Testing
- OMNIPHYS Multimodal Ultrasound Imaging System
- Where
- United States
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Truway Health, Inc.